name	nt_name	aa_name	multi_aa_name	multiaa_mutation_split_names	start	vcf_gene	chrom_region	mutation_type	dp	obs_sample_size	variant_pop_size	ps_filter	ps_exc	mat_pep_id	mat_pep_desc	mat_pep_acc	ro	ao_by_var_seq	ao	variant_seq	reference_seq	function_category	citation	citation_url	comb_mutation	function_description	heterozygosity	viral_lineages	clade_defining_status	status	voi_designation_date	voc_designation_date	vum_designation_date
A1397A	g.C4191T	p.A1397A			4456	ORF1ab	ORF1a	SILENT	272	272	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		269	T=3	3	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
A1679V	g.C5036T	p.A1679V			5301	ORF1ab	ORF1a	MISSENSE	272	272	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		261	T=11	11	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
A33S	g.G97T	p.A33S			25489	ORF3a	ORF3a	MISSENSE	272	272	0						251	T=21	21	T	G						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
A3956V	g.C11867T	p.A3956V			12132	ORF1ab	ORF1a	MISSENSE	272	272	0			nsp8	produced by both pp1a and pp1ab		269	T=3	3	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
A4016V	g.C12047T	p.A4016V			12312	ORF1ab	ORF1a	MISSENSE	272	272	0			nsp8	produced by both pp1a and pp1ab		270	T=2	2	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
A5778V	g.C17333T	p.A5778V			17597	ORF1ab	ORF1b	MISSENSE	272	272	0			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		270	T=2	2	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
A6269A	g.T18807C	p.A6269A			19071	ORF1ab	ORF1b	SILENT	272	272	0			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		270	C=2	2	C	T						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
A656V	g.C1967T	p.A656V			2232	ORF1ab	ORF1a	MISSENSE	272	272	0			nsp2	produced by both pp1a and pp1ab		227	T=45	45	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
A65S	g.G193T	p.A65S			28086	ORF8	ORF8	MISSENSE	272	272	0						267	T=5	5	T	G						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
A684V	g.C2051T	p.A684V			23613	S	S	MISSENSE	271	272	0						269	T=2	2	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
A701V	g.C2102T	p.A701V			23664	S	S	MISSENSE	271	272	0						14	T=257	257	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed essentially no change in binding (KD) relative to D614G.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
A701V	g.C2102T	p.A701V			23664	S	S	MISSENSE	271	272	0						14	T=257	257	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L5F', 'T95I', 'D253G', 'E484K'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.526) showed a 1.78x increase  in binding (KD) relative to D614G, even though each variant independently decreases binding.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
A701V	g.C2102T	p.A701V			23664	S	S	MISSENSE	271	272	0						14	T=257	257	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
A701V	g.C2102T	p.A701V			23664	S	S	MISSENSE	271	272	0						14	T=257	257	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L5F', 'T95I', 'D253G', 'E484K'	This variant combination (representing lineage B.1.526) showed a 1.02x increase in Spike binding (relative  to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
A701V	g.C2102T	p.A701V			23664	S	S	MISSENSE	271	272	0						14	T=257	257	T	C	convalescent plasma escape	Zhou et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1	'L5F', 'T95I', 'D253G', 'E484K', 'D614G'	"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.8x reduction in  IC50 serum dilution concentration for 6 convalescent sera."	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
A701V	g.C2102T	p.A701V			23664	S	S	MISSENSE	271	272	0						14	T=257	257	T	C	convalescent plasma escape	Zhou et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1	'L5F', 'T95I', 'D253G', 'S477N', 'D614G'	"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed no significant  change in IC50 serum dilution concentration for 6 convalescent sera."	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
A701V	g.C2102T	p.A701V			23664	S	S	MISSENSE	271	272	0						14	T=257	257	T	C	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
A701V	g.C2102T	p.A701V			23664	S	S	MISSENSE	271	272	0						14	T=257	257	T	C	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'L5F', 'T95I', 'D253G', 'S477N', 'D614G'	Neutralization efficiency (ID50) against B.1.526 reduced 2.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
A701V	g.C2102T	p.A701V			23664	S	S	MISSENSE	271	272	0						14	T=257	257	T	C	vaccine neutralization efficacy	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L5F', 'T95I', 'D253G', 'E484K', 'D614G'	2.3x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
A701V	g.C2102T	p.A701V			23664	S	S	MISSENSE	271	272	0						14	T=257	257	T	C	vaccine neutralization efficacy	Pegu et al (2021)	https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1	'L5F', 'T95I', 'D253G', 'E484K', 'D614G'	Detectable antibodies against B.1.526+E484K at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 43 100%, Day 209 88%.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
A701V	g.C2102T	p.A701V			23664	S	S	MISSENSE	271	272	0						14	T=257	257	T	C	vaccine neutralization efficacy	Zhou et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1	'L5F', 'T95I', 'D253G', 'E484K', 'D614G'	"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.6x reduction in both IC50 serum dilution concentration for sera from 5 BNT162b2 (Pzifer) or 3 mRNA1273 (Moderna) vacinees collected 28 days following booster dose."	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
A701V	g.C2102T	p.A701V			23664	S	S	MISSENSE	271	272	0						14	T=257	257	T	C	vaccine neutralization efficacy	Zhou et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1	'L5F', 'T95I', 'D253G', 'S477N', 'D614G'	"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed no significant change in IC50 serum dilution concentration for sera from BNT162b2 (Pzifer) or mRNA1273 (Moderna) vacinees collected 28 days following booster dose."	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
A701V	g.C2102T	p.A701V			23664	S	S	MISSENSE	271	272	0						14	T=257	257	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
A701V	g.C2102T	p.A701V			23664	S	S	MISSENSE	271	272	0						14	T=257	257	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L5F', 'T95I', 'D253G', 'E484K'	This variant combination (representing lineage B.1.526) showed a 1.34x increase in Spike binding (relative  to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
A701V	g.C2102T	p.A701V			23664	S	S	MISSENSE	271	272	0						14	T=257	257	T	C	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is -0.33 kcal/mol (i.e. destabilizing relative to wild type) 	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D1260N	g.G3778A	p.D1260N			25340	S	S	MISSENSE	272	272	0						270	A=2	2	A	G						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
D253G	g.A758G	p.D253G			22320	S	S	MISSENSE	267	272	0						0	G=267	267	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.08x decrease in binding (KD) relative to D614G.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D253G	g.A758G	p.D253G			22320	S	S	MISSENSE	267	272	0						0	G=267	267	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L5F', 'T95I', 'E484K', 'A701V'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.526) showed a 1.78x increase  in binding (KD) relative to D614G, even though each variant independently decreases binding.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D253G	g.A758G	p.D253G			22320	S	S	MISSENSE	267	272	0						0	G=267	267	G	A	antibody epitope effects	McCallum et al. (2021)	https://doi.org/10.1101/2021.01.14.426475		"Massive reduction in S2L28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i"", but no effect on other mAbs within that supersite"	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D253G	g.A758G	p.D253G			22320	S	S	MISSENSE	267	272	0						0	G=267	267	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D253G	g.A758G	p.D253G			22320	S	S	MISSENSE	267	272	0						0	G=267	267	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L5F', 'T95I', 'E484K', 'A701V'	This variant combination (representing lineage B.1.526) showed a 1.02x increase in Spike binding (relative  to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D253G	g.A758G	p.D253G			22320	S	S	MISSENSE	267	272	0						0	G=267	267	G	A	convalescent plasma escape	Zhou et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1	'L5F', 'T95I', 'E484K', 'D614G', 'A701V'	"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.8x reduction in  IC50 serum dilution concentration for 6 convalescent sera."	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D253G	g.A758G	p.D253G			22320	S	S	MISSENSE	267	272	0						0	G=267	267	G	A	convalescent plasma escape	Zhou et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1	'L5F', 'T95I', 'S477N', 'D614G', 'A701V'	"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed no significant  change in IC50 serum dilution concentration for 6 convalescent sera."	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D253G	g.A758G	p.D253G			22320	S	S	MISSENSE	267	272	0						0	G=267	267	G	A	monoclonal antibody serial passage escape	McCallum et al. (2021)	https://doi.org/10.1101/2021.01.14.426475		Escape mutation against Spike N terminal domain antigenic supersite i mAb S2L28	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D253G	g.A758G	p.D253G			22320	S	S	MISSENSE	267	272	0						0	G=267	267	G	A	outcome hazard ratio	Yang et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.08.04.21261596v1	'T95I', 'D614G'	B.1.526 (Iota) substantially increased IFR in older adults: by 46% (95% CI: 7.4 – 84%) among 45-64 year-olds,  82% (95% CI: 20 – 140%) among 65-74 year-olds, and 62% (95% CI: 45 – 80%) among 75+ during Nov 2020 – Apr 2021,  compared to baseline IFR estimated for preexisting variants. [minimum clade defining mutations listed]	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D253G	g.A758G	p.D253G			22320	S	S	MISSENSE	267	272	0						0	G=267	267	G	A	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'L5F', 'T95I', 'S477N', 'D614G', 'A701V'	Neutralization efficiency (ID50) against B.1.526 reduced 2.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D253G	g.A758G	p.D253G			22320	S	S	MISSENSE	267	272	0						0	G=267	267	G	A	vaccine neutralization efficacy	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L5F', 'T95I', 'E484K', 'D614G', 'A701V'	2.3x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D253G	g.A758G	p.D253G			22320	S	S	MISSENSE	267	272	0						0	G=267	267	G	A	vaccine neutralization efficacy	Pegu et al (2021)	https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1	'L5F', 'T95I', 'E484K', 'D614G', 'A701V'	Detectable antibodies against B.1.526+E484K at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 43 100%, Day 209 88%.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D253G	g.A758G	p.D253G			22320	S	S	MISSENSE	267	272	0						0	G=267	267	G	A	vaccine neutralization efficacy	Zhou et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1	'L5F', 'T95I', 'E484K', 'D614G', 'A701V'	"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.6x reduction in both IC50 serum dilution concentration for sera from 5 BNT162b2 (Pzifer) or 3 mRNA1273 (Moderna) vacinees collected 28 days following booster dose."	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D253G	g.A758G	p.D253G			22320	S	S	MISSENSE	267	272	0						0	G=267	267	G	A	vaccine neutralization efficacy	Zhou et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1	'L5F', 'T95I', 'S477N', 'D614G', 'A701V'	"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed no significant change in IC50 serum dilution concentration for sera from BNT162b2 (Pzifer) or mRNA1273 (Moderna) vacinees collected 28 days following booster dose."	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D253G	g.A758G	p.D253G			22320	S	S	MISSENSE	267	272	0						0	G=267	267	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	No significant change in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D253G	g.A758G	p.D253G			22320	S	S	MISSENSE	267	272	0						0	G=267	267	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L5F', 'T95I', 'E484K', 'A701V'	This variant combination (representing lineage B.1.526) showed a 1.34x increase in Spike binding (relative  to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D2848D	g.C8544T	p.D2848D			8809	ORF1ab	ORF1a	SILENT	271	272	0			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		257	T=14	14	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
D4454G	g.A13361G	p.D4454G			13625	ORF1ab	ORF1b	MISSENSE	270	272	0			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		139	G=131	131	G	A						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
D5152D	g.C15456T	p.D5152D			15720	ORF1ab	ORF1b	SILENT	269	272	0			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		209	T=60	60	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'A701V'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed essentially no change in binding (KD) relative to D614G.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D253G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.08x decrease in binding (KD) relative to D614G.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'E484K'	This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L5F'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L5F', 'T95I', 'D253G', 'E484K', 'A701V'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.526) showed a 1.78x increase  in binding (KD) relative to D614G, even though each variant independently decreases binding.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'T95I'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x decrease in binding (KD) relative to D614G.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	ACE2 receptor binding affinity	Li et al. (2020)	https://doi.org/10.1016/j.cell.2020.07.012		In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'A701V'	1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D253G'	1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'E484K'	1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L5F'	No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L5F', 'T95I', 'D253G', 'E484K', 'A701V'	This variant combination (representing lineage B.1.526) showed a 1.02x increase in Spike binding (relative  to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'T95I'	No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'E484K'	Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint]	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'S477N'	Lentiviral pseudotyped with the key mutations from 20A.EU2 lineage was neutralized slightly less than D614G in 10 convalescent sera from April 2020 infectees.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	convalescent plasma escape	Zhou et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1	'L5F', 'T95I', 'D253G', 'E484K', 'A701V'	"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.8x reduction in  IC50 serum dilution concentration for 6 convalescent sera."	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	convalescent plasma escape	Zhou et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1	'L5F', 'T95I', 'D253G', 'S477N', 'A701V'	"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed no significant  change in IC50 serum dilution concentration for 6 convalescent sera."	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	immunosuppression variant emergence	Landis et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.08.21256775v1		Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	outcome hazard ratio	Yang et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.08.04.21261596v1	'T95I', 'D253G'	B.1.526 (Iota) substantially increased IFR in older adults: by 46% (95% CI: 7.4 – 84%) among 45-64 year-olds,  82% (95% CI: 20 – 140%) among 65-74 year-olds, and 62% (95% CI: 45 – 80%) among 75+ during Nov 2020 – Apr 2021,  compared to baseline IFR estimated for preexisting variants. [minimum clade defining mutations listed]	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	reinfection	Fournier et al. (2021)	https://doi.org/10.1016/j.ijid.2021.03.068	'S477N'	"11 cases of re-infection with the ""Marseille-4"" variant found within 1028 positive tests, where all of the earlier infections were from different strains. This lineage is also characterized by N:p.M234I:A376T"	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	symptom prevalence	Fournier et al. (2021)	https://doi.org/10.1016/j.ijid.2021.03.068	'S477N'	Compared to the clade 20A strains that predominated during phase 1 between March and May 2020, the Marseille-4 variant (characterized  by this mutation plus N:p.M234I:A376T) was associated with a lower frequency of cough, rhinitis, and olfactory and gustatory disorders.  By contrast, hypoxemia was more frequent in patients infected with the Marseille-4 variant.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	tissue specific neutralization	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5		The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract. 	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	trafficking	Barrett et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1		Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry)	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	trafficking	Daniloski et al. (2021)	https://doi.org/10.7554/elife.65365		The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K'	~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	trafficking	Ozono et al. (2020)	https://www.nature.com/articles/s41467-021-21118-2		Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses. 	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'S477N'	Lentiviral pseudotyped with the key mutations from 20A.EU2 lineage was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no significant change in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	trafficking	Zhang et l. (2020)	https://www.nature.com/articles/s41467-020-19808-4		We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'L5F', 'T95I', 'D253G', 'S477N', 'A701V'	Neutralization efficiency (ID50) against B.1.526 reduced 2.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013		Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	vaccine neutralization efficacy	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L5F', 'T95I', 'D253G', 'E484K', 'A701V'	2.3x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008		Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset. 	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K'	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	vaccine neutralization efficacy	Pegu et al (2021)	https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1	'L5F', 'T95I', 'D253G', 'E484K', 'A701V'	Detectable antibodies against B.1.526+E484K at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 43 100%, Day 209 88%.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	vaccine neutralization efficacy	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'E484K'	Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	vaccine neutralization efficacy	Zhou et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1	'L5F', 'T95I', 'D253G', 'E484K', 'A701V'	"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.6x reduction in both IC50 serum dilution concentration for sera from 5 BNT162b2 (Pzifer) or 3 mRNA1273 (Moderna) vacinees collected 28 days following booster dose."	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	vaccine neutralization efficacy	Zhou et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1	'L5F', 'T95I', 'D253G', 'S477N', 'A701V'	"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed no significant change in IC50 serum dilution concentration for sera from BNT162b2 (Pzifer) or mRNA1273 (Moderna) vacinees collected 28 days following booster dose."	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'A701V'	1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D253G'	No significant change in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'E484K'	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L5F'	1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L5F', 'T95I', 'D253G', 'E484K', 'A701V'	This variant combination (representing lineage B.1.526) showed a 1.34x increase in Spike binding (relative  to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'T95I'	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	viral load	Plante et al. (2020)	https://www.nature.com/articles/s41586-020-2895-3		Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type) 	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	virion structure	Weissman et al. (2020)	https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2		"Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	virion structure	Yurkovetskiy et al. (2020)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492024/		"CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	272	272	0						0	G=272	272	G	A	virion structure	Zhang et al. (2020)	https://www.nature.com/articles/s41467-020-19808-4		Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
D61D	g.T183C	p.D61D			27384	ORF6	ORF6	SILENT	272	272	0						235	C=37	37	C	T						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
D627D	g.T1881C	p.D627D			23443	S	S	SILENT	272	272	0						264	C=8	8	C	T						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
E1013D	g.G3039T	p.E1013D			3304	ORF1ab	ORF1a	MISSENSE	271	272	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		267	T=4	4	T	G						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
E1142D	g.A3426C	p.E1142D			3691	ORF1ab	ORF1a	MISSENSE	272	272	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		270	C=2	2	C	A						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
E13D	g.G39T	p.E13D			27240	ORF6	ORF6	MISSENSE	272	272	0						270	T=2	2	T	G						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	ACE2 receptor binding affinity	Collier et al. (2021)	https://www.nature.com/articles/s41586-021-03412-7		This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L5F', 'T95I', 'D253G', 'A701V'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.526) showed a 1.78x increase  in binding (KD) relative to D614G, even though each variant independently decreases binding.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	ACE2 receptor binding affinity	Laffeber et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1		RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	ACE2 receptor binding affinity	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	ACE2 receptor binding affinity	Ramanathan et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1		Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	ACE2 receptor binding affinity	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, ACE2 binding affinity increased 0.06 fold	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported moderate increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	ACE2 receptor binding affinity	Vogel et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1		The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	ACE2 receptor binding affinity	Zahradnik et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.06.425392		Among the first selected variants in an in vitro evolution experiment for ACE2 binding.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	T cell evasion	Reynolds et al. (2021)	https://science.sciencemag.org/content/early/2021/04/29/science.abh1282		Analyzing responses to the E484K mutation seen in B.1.351 and P.1 variants, we noted that it did  not fall in a region predicted to bind the HLAII alleles tested (table S4). The mutation appeared  to have no substantial or differential impact on T cell responses.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w		Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384 and S2H58.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	antibody epitope effects	Collier et al. (2021)	https://www.nature.com/articles/s41586-021-03412-7		Of 50 mAbs tested, major loss of neutralization observed for S2N28, S2X615, S2N12, S2X192, S2H7, S2X16, S2X58, S2H70, S2X613, S2D19, S2N22, S2D32, S2H58, S2M11, S2D106, S2X30.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	antibody epitope effects	Gaebler et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2		Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant. 	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	antibody epitope effects	Li et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.19.440481v1		Monoclonal antibodies 13G9 and 58G6 maintain fairly high neutralization potency, compared to others interfacing with E484K.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	antibody epitope effects	Liu et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2		Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	antibody epitope effects	Rappazzo et al. (2021)	https://science.sciencemag.org/content/371/6531/823		Massive reduction in binding efficiency vs wild type for mAb LY-CoV555.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	antibody epitope effects	Sun et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1		Complete loss of binding in ELISA by the variant against monoclonal antibody VH-Fc ab8	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	antibody epitope effects	Wang et al. (2021)	https://www.nature.com/articles/s41586-021-03398-2		Pseudotyped virus model ablates neutralization by RBD-directed mAbs 4-20, 2-4, 2-43, 2-30, 2-15, LY-Cov555, C121. Pseudotyped virus model impairs neutralization by RBD-directed mAb COV2-2196 (somewhat more than fully pseudotyped B.1.351 or live virus)	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	antibody epitope effects	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		Resistent to all seven class 2 (Spike 'up' or 'down' conformation, RBD targeting) antibodies tested, with 10-fold  or greater reduction in neutralization (plus notable reudction in two unclassfied mAbs).	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L5F', 'T95I', 'D253G', 'A701V'	This variant combination (representing lineage B.1.526) showed a 1.02x increase in Spike binding (relative  to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	convalescent plasma escape	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1		Average ~5-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	convalescent plasma escape	Andreano et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.12.28.424451		This mutation occurred in 100% of sequenced virions after 12 passages and led to a 4-fold decrease in convalescent plasma neutralization activity	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	convalescent plasma escape	Cele et al. (2021)	https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf		The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	convalescent plasma escape	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2		Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest concentration (1:80 initial dilution) of all 4 convalescent sera tested (triplicate experiments). Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	convalescent plasma escape	Schmidt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1		Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		The only mutation in the B.1.351 lineage that appears to contribute to neutralization reduction (~1.7x across 10 convalescent sera from April 2020 infectees)	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'D614G'	Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint]	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	convalescent plasma escape	Tang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1		As measured by surface plasmon resonance, RBD with the E484K mutation alone showed a mean 19.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	convalescent plasma escape	Wang et al. (2021)	https://www.nature.com/articles/s41586-021-03398-2		The neutralizing activity of 15/20 convalescent sera was significantly lower against this pseudotyped virus model	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres "	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight."	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	convalescent plasma escape	Zhou et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1		"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.3x reduction in  IC50 serum dilution concentration for 6 convalescent sera."	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	convalescent plasma escape	Zhou et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1	'L5F', 'T95I', 'D253G', 'D614G', 'A701V'	"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.8x reduction in  IC50 serum dilution concentration for 6 convalescent sera."	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	monoclonal antibody serial passage escape	Barnes et al. (2020)	https://www.nature.com/articles/s41586-020-2852-1_reference.pdf?origin		The engineered mutation cause 10-fold or more increase in the disassociation constant with many monoclonal antibodies (C144/C002/C121/C104/C110).	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	monoclonal antibody serial passage escape	Baum et al. (2020)	http://dx.doi.org/10.1126/science.abd0831		Escape variant 100% appearance in 2 passages against Regeneron monoclonal antibody REGN10989 @ 50ug/mL (99% after one passage)	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	monoclonal antibody serial passage escape	Greaney et al. (2020)	https://doi.org/10.1016/j.chom.2020.11.007		Mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody Effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	monoclonal antibody serial passage escape	Starr et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1		Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	monoclonal antibody serial passage escape	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		Class 2 antibodies C627, C602, C671, C643, and class 2/3 antibody C603 selected for the emergence of the E484K mutation in vitro.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	monoclonal antibody serial passage escape	Weisblum et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf		Strong positive selection (up to 50% of supernatant sequences) after C121 monoclonal antibody assay, decreasing in subsequent passages Strong positive selection (up to 44% of supernatant sequences) after after one round of C144 monoclonal antibody passage, then waning on subsequent passages	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		Bamlanivimab (LY-CoV555) lost ~16x binding against this isolated mutation. Casirivimab lost ~16x binding against this isolated mutation.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	'S477N'	Bamlanivimab (LY-CoV555) lost ~10x binding against this double mutation. Tixagevimab lost ~16x binding against this double mutation.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	pharmaceutical effectiveness	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	trafficking	Ferriera et al (2021)	https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1		This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. 	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no change in infection rate amongst the cells.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	vaccine neutralization efficacy	Ferreira et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1		Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. E484K conferred a ten-fold reduction in neutralisation by vaccine sera.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	vaccine neutralization efficacy	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L5F', 'T95I', 'D253G', 'D614G', 'A701V'	2.3x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	vaccine neutralization efficacy	Ikegame et al. (2021)	https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1		E484K pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed a mean 2.8x decrease in neutralization effiacacy.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	vaccine neutralization efficacy	Jangra et al. (2021)	https://doi.org/10.1016/S2666-5247(21		Human sera from 5 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) neutralized this variant 3.4x less relative to reference  USA-WA1/2020 strain. 8 convalescent plasma with weak IgG ELISA titre neutralized this variant 2.4x less relative to reference  USA-WA1/2020 strain. One plasma failed to neutralize at all. 11 convalescent plasma with moderate IgG ELISA titre neutralized this variant 4.2x less relative to reference  USA-WA1/2020 strain.  11 convalescent plasma with high IgG ELISA titre neutralized this variant 2.6x less relative to reference  USA-WA1/2020 strain. 	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	vaccine neutralization efficacy	Pegu et al (2021)	https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1	'L5F', 'T95I', 'D253G', 'D614G', 'A701V'	Detectable antibodies against B.1.526+E484K at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 43 100%, Day 209 88%.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	vaccine neutralization efficacy	Solfrosi et al. (2021)	https://doi.org/10.1084/jem.20202756		Neutralizing antibody titers of non-human primate sera after one or two doses of Ad26.COV2.S (Jannsen vaccine)  against the variants containing the E484K substitution in the RBD were present but reduced  (fold reduction between 3.35–7.78, 95% confidence interval all above twofold difference, one-sample t test). 	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	vaccine neutralization efficacy	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'D614G'	Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	vaccine neutralization efficacy	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  ELISA tests show 10x reduced efficacy of a majority of isolated antibodies, but only a modest decrease for vaccine plasma overall.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	vaccine neutralization efficacy	Zhou et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1	'L5F', 'T95I', 'D253G', 'D614G', 'A701V'	"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.6x reduction in both IC50 serum dilution concentration for sera from 5 BNT162b2 (Pzifer) or 3 mRNA1273 (Moderna) vacinees collected 28 days following booster dose."	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L5F', 'T95I', 'D253G', 'A701V'	This variant combination (representing lineage B.1.526) showed a 1.34x increase in Spike binding (relative  to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	272	272	0						18	A=254	254	A	G	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is -0.6 kcal/mol (i.e. destabilizing relative to wild type) 	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
E92K	g.G274A	p.E92K			27667	ORF7a	ORF7a	MISSENSE	272	272	0						268	A=4	4	A	G						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
F3329F	g.C9987T	p.F3329F			10252	ORF1ab	ORF1a	SILENT	272	272	0			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		269	T=3	3	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
F3486S	g.T10457C	p.F3486S			10722	ORF1ab	ORF1a	MISSENSE	272	272	0			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		267	C=5	5	C	T						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
F5348F	g.C16044T	p.F5348F			16308	ORF1ab	ORF1b	SILENT	270	272	0			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		268	T=2	2	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
F53F	g.C159T	p.F53F			26681	M	M	SILENT	272	272	0						235	T=37	37	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
F924F	g.C2772T	p.F924F			3037	ORF1ab	ORF1a	SILENT	271	272	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		0	T=271	271	T	C						False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
G1946S	g.G5836A	p.G1946S			6101	ORF1ab	ORF1a	MISSENSE	270	272	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		255	A=15	15	A	G						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
G243C	g.G727T	p.G243C			29000	N	N	MISSENSE	269	272	0						227	T=42	42	T	G						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
G254R	g.G760A	p.G254R			26152	ORF3a	ORF3a	MISSENSE	272	272	0						262	A=10	10	A	G						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
G328G	g.A984C	p.G328G			29257	N	N	SILENT	272	272	0						270	C=2	2	C	A						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
G4571G	g.T13713C	p.G4571G			13977	ORF1ab	ORF1b	SILENT	272	272	0			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		269	C=3	3	C	T						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
G75S	g.G223A	p.G75S			21785	S	S	MISSENSE	272	272	0						140	A=131	131	A	G						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
G8R	g.G22A	p.G8R			27915	ORF8	ORF8	MISSENSE	272	272	0						258	A=14	14	A	G						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
H300Y	g.C898T	p.H300Y			29171	N	N	MISSENSE	272	272	0						268	T=4	4	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
I3055I	g.C9165T	p.I3055I			9430	ORF1ab	ORF1a	SILENT	272	272	0			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		261	T=11	11	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
I3779T	g.T11336C	p.I3779T			11601	ORF1ab	ORF1a	MISSENSE	272	272	0			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		266	C=6	6	C	T						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
K1817N	g.G5451T	p.K1817N			5716	ORF1ab	ORF1a	MISSENSE	272	272	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		141	T=131	131	T	G						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
K192K	g.A576G	p.K192K			25968	ORF3a	ORF3a	SILENT	272	272	0						258	G=14	14	G	A						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
K4232R	g.A12695G	p.K4232R			12960	ORF1ab	ORF1a	MISSENSE	272	272	0			nsp9	ssRNA-binding protein, produced by both pp1a and pp1ab		264	G=8	8	G	A						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
K6274N	g.G18822T	p.K6274N			19086	ORF1ab	ORF1b	MISSENSE	272	272	0			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		258	T=14	14	T	G						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
K798N	g.G2394T	p.K798N			2659	ORF1ab	ORF1a	MISSENSE	271	272	0			nsp2	produced by both pp1a and pp1ab		269	T=2	2	T	G						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
L116F	g.C346T	p.L116F			27739	ORF7a	ORF7a	MISSENSE	272	272	0						258	T=14	14	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
L3180L	g.G9540T	p.L3180L			9805	ORF1ab	ORF1a	SILENT	272	272	0			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		269	T=3	3	T	G						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
L3201P	g.T9602C	p.L3201P			9867	ORF1ab	ORF1a	MISSENSE	272	272	0			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		0	C=272	272	C	T						False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
L32F	g.C94T	p.L32F			27847	ORF7b	ORF7b	MISSENSE	272	272	0						141	CAT=128	128	CAT	CAC						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
L3330F	g.G9990T	p.L3330F			10255	ORF1ab	ORF1a	MISSENSE	272	272	0			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		270	T=2	2	T	G						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
L3338F	g.C10012T	p.L3338F			10277	ORF1ab	ORF1a	MISSENSE	272	272	0			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		141	T=131	131	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
L3606F	g.G10818T	p.L3606F			11083	ORF1ab	ORF1a	MISSENSE	272	272	0	mask	highly_homoplasic	nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		269	T=3	3	T	G						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
L3796L	g.C11388T	p.L3796L			11653	ORF1ab	ORF1a	SILENT	272	272	0			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		270	T=2	2	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
L5230L	g.C15688T	p.L5230L			15952	ORF1ab	ORF1b	SILENT	270	272	0			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		268	T=2	2	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
L5580L	g.C16740T	p.L5580L			17004	ORF1ab	ORF1b	SILENT	272	272	0			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		262	T=10	10	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
L5F	g.C13T	p.L5F			21575	S	S	MISSENSE	270	272	0	mask	highly_homoplasic				0	T=270	270	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
L5F	g.C13T	p.L5F			21575	S	S	MISSENSE	270	272	0	mask	highly_homoplasic				0	T=270	270	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'T95I', 'D253G', 'E484K', 'A701V'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.526) showed a 1.78x increase  in binding (KD) relative to D614G, even though each variant independently decreases binding.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
L5F	g.C13T	p.L5F			21575	S	S	MISSENSE	270	272	0	mask	highly_homoplasic				0	T=270	270	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
L5F	g.C13T	p.L5F			21575	S	S	MISSENSE	270	272	0	mask	highly_homoplasic				0	T=270	270	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'T95I', 'D253G', 'E484K', 'A701V'	This variant combination (representing lineage B.1.526) showed a 1.02x increase in Spike binding (relative  to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
L5F	g.C13T	p.L5F			21575	S	S	MISSENSE	270	272	0	mask	highly_homoplasic				0	T=270	270	T	C	convalescent plasma escape	Zhou et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1	'T95I', 'D253G', 'E484K', 'D614G', 'A701V'	"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.8x reduction in  IC50 serum dilution concentration for 6 convalescent sera."	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
L5F	g.C13T	p.L5F			21575	S	S	MISSENSE	270	272	0	mask	highly_homoplasic				0	T=270	270	T	C	convalescent plasma escape	Zhou et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1	'T95I', 'D253G', 'S477N', 'D614G', 'A701V'	"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed no significant  change in IC50 serum dilution concentration for 6 convalescent sera."	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
L5F	g.C13T	p.L5F			21575	S	S	MISSENSE	270	272	0	mask	highly_homoplasic				0	T=270	270	T	C	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'T95I', 'D253G', 'S477N', 'D614G', 'A701V'	Neutralization efficiency (ID50) against B.1.526 reduced 2.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
L5F	g.C13T	p.L5F			21575	S	S	MISSENSE	270	272	0	mask	highly_homoplasic				0	T=270	270	T	C	vaccine neutralization efficacy	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'T95I', 'D253G', 'E484K', 'D614G', 'A701V'	2.3x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
L5F	g.C13T	p.L5F			21575	S	S	MISSENSE	270	272	0	mask	highly_homoplasic				0	T=270	270	T	C	vaccine neutralization efficacy	Pegu et al (2021)	https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1	'T95I', 'D253G', 'E484K', 'D614G', 'A701V'	Detectable antibodies against B.1.526+E484K at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 43 100%, Day 209 88%.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
L5F	g.C13T	p.L5F			21575	S	S	MISSENSE	270	272	0	mask	highly_homoplasic				0	T=270	270	T	C	vaccine neutralization efficacy	Zhou et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1	'T95I', 'D253G', 'E484K', 'D614G', 'A701V'	"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.6x reduction in both IC50 serum dilution concentration for sera from 5 BNT162b2 (Pzifer) or 3 mRNA1273 (Moderna) vacinees collected 28 days following booster dose."	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
L5F	g.C13T	p.L5F			21575	S	S	MISSENSE	270	272	0	mask	highly_homoplasic				0	T=270	270	T	C	vaccine neutralization efficacy	Zhou et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1	'T95I', 'D253G', 'S477N', 'D614G', 'A701V'	"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed no significant change in IC50 serum dilution concentration for sera from BNT162b2 (Pzifer) or mRNA1273 (Moderna) vacinees collected 28 days following booster dose."	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
L5F	g.C13T	p.L5F			21575	S	S	MISSENSE	270	272	0	mask	highly_homoplasic				0	T=270	270	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
L5F	g.C13T	p.L5F			21575	S	S	MISSENSE	270	272	0	mask	highly_homoplasic				0	T=270	270	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'T95I', 'D253G', 'E484K', 'A701V'	This variant combination (representing lineage B.1.526) showed a 1.34x increase in Spike binding (relative  to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
L6666L	g.A19998G	p.L6666L			20262	ORF1ab	ORF1b	SILENT	270	272	0			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only		0	G=270	270	G	A						False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
L96L	g.C288T	p.L96L			25680	ORF3a	ORF3a	SILENT	272	272	0						268	T=4	4	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
M109I	g.G327T	p.M109I			26849	M	M	MISSENSE	272	272	0						227	T=45	45	T	G						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
M1312I	g.G3936T	p.M1312I			4201	ORF1ab	ORF1a	MISSENSE	272	272	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		268	T=4	4	T	G						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
M1fs	g.1delA	p.M1fs			28270	N	intergenic		268	272	0			(N|GU280_gp10|1|1.00)			2	TAAATG=266	266	TAAATG	TAAAATG						False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
M234I	g.G702A	p.M234I			28975	N	N	MISSENSE	272	272	0						14	A=258	258	A	G						False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
M3712V	g.A11134G	p.M3712V			11399	ORF1ab	ORF1a	MISSENSE	272	272	0			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		269	G=3	3	G	A						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
N154I	g.A461T	p.N154I			28734	N	N	MISSENSE	272	272	0						267	T=5	5	T	A						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
N2038N	g.T6114C	p.N2038N			6379	ORF1ab	ORF1a	SILENT	271	272	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		264	C=7	7	C	T						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
N2482N	g.T7446C	p.N2482N			7711	ORF1ab	ORF1a	SILENT	272	272	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		270	C=2	2	C	T						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
N4235N	g.C12705T	p.N4235N			12970	ORF1ab	ORF1a	SILENT	272	272	0			nsp9	ssRNA-binding protein, produced by both pp1a and pp1ab		270	T=2	2	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
N6055N	g.T18165C	p.N6055N			18429	ORF1ab	ORF1b	SILENT	271	272	0			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		269	C=2	2	C	T						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
P10L	g.C29T	p.P10L			29586	ORF10	ORF10	MISSENSE	272	272	0						270	T=2	2	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
P13L	g.C38T	p.P13L			28311	N	N	MISSENSE	272	272	0						258	T=14	14	T	C	T cell evasion	de Silva et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1		Variant causes complete loss of T cell line responsiveness to B*27:05-restricted CD8+ N epitope QRNAPRITF 1-17(2,13).	False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
P13L	g.C38T	p.P13L			28311	N	N	MISSENSE	272	272	0						258	T=14	14	T	C	homoplasy	Borges et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.19.444774v1		In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent. 	False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
P1921S	g.C5761T	p.P1921S			6026	ORF1ab	ORF1a	MISSENSE	269	272	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		266	T=3	3	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
P199L	g.C596T	p.P199L			28869	N	N	MISSENSE	272	272	0						14	T=258	258	T	C	RNA binding	Syed et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.05.455082v1		Northern blot analysis of novel mutant virus-like-particles (VLPs) shows increase in RNA content with this mutation, suggesting that it improves virus particle production (requisite RNA packaging signal binding site in nsp15/16 boundary is included in the VLP).	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
P309P	g.C927T	p.P309P			29200	N	N	SILENT	272	272	0						267	T=5	5	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
P3371S	g.C10111T	p.P3371S			10376	ORF1ab	ORF1a	MISSENSE	272	272	0			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		267	T=5	5	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
P3504S	g.C10510T	p.P3504S			10775	ORF1ab	ORF1a	MISSENSE	272	272	0			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		269	T=3	3	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
P42L	g.C125T	p.P42L			25517	ORF3a	ORF3a	MISSENSE	209	272	0						0	T=209	209	T	C						False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
P4715L	g.C14144T	p.P4715L			14408	ORF1ab	ORF1b	MISSENSE	272	272	0			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		0	T=272	272	T	C						False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
P4731P	g.A14193T	p.P4731P			14457	ORF1ab	ORF1b	SILENT	272	272	0			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		252	T=20	20	T	A						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
P6657S	g.C19969T	p.P6657S			20233	ORF1ab	ORF1b	MISSENSE	269	272	0			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only		264	T=5	5	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
P6932S	g.C20794T	p.P6932S			21058	ORF1ab	ORF1b	MISSENSE	271	272	0			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only		267	T=4	4	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
P99L	g.C296T	p.P99L			27689	ORF7a	ORF7a	MISSENSE	272	272	0						269	T=3	3	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
Q18X	g.C52T	p.Q18X			27945	ORF8	ORF8	NONSENSE	272	272	0						268	T=4	4	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
Q5412H	g.A16236C	p.Q5412H			16500	ORF1ab	ORF1b	MISSENSE	270	272	0			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		0	C=270	270	C	A						False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
Q57H	g.G171T	p.Q57H			25563	ORF3a	ORF3a	MISSENSE	272	272	0						0	T=272	272	T	G						False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
Q957R	g.A2870G	p.Q957R			24432	S	S	MISSENSE	271	272	0						257	G=14	14	G	A						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
R14C	g.C40T	p.R14C			28313	N	N	MISSENSE	272	272	0						270	T=2	2	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
R2985R	g.G8955A	p.R2985R			9220	ORF1ab	ORF1a	SILENT	272	272	0			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		261	A=11	11	A	G						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
R29H	g.G86A	p.R29H			351	ORF1ab	ORF1a	MISSENSE	272	272	0			leader protein	nsp1, produced by both pp1a and pp1ab		268	A=4	4	A	G						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
R4784R	g.C14352T	p.R4784R			14616	ORF1ab	ORF1b	SILENT	272	272	0			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		270	T=2	2	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
S2015S	g.C6045T	p.S2015S			6310	ORF1ab	ORF1a	SILENT	272	272	0	caution	neighbour_linked	nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		268	T=4	4	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
S202R	g.T606G	p.S202R			28879	N	N	MISSENSE	272	272	0						258	G=14	14	G	T	RNA binding	Syed et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.05.455082v1		Northern blot analysis of novel mutant virus-like-particles (VLPs) shows major increase in RNA content with this mutation, suggesting that  it improves virus particle production (requisite RNA packaging signal binding site in nsp15/16 boundary is included in the VLP).	False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
S2312S	g.A6936G	p.S2312S			7201	ORF1ab	ORF1a	SILENT	271	272	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		256	G=15	15	G	A						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
S2981F	g.C8942T	p.S2981F			9207	ORF1ab	ORF1a	MISSENSE	272	272	0			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		214	T=58	58	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
S3601S	g.T10803G	p.S3601S			11068	ORF1ab	ORF1a	SILENT	272	272	0			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		268	G=4	4	G	T						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
S443F	g.C1328T	p.S443F			1593	ORF1ab	ORF1a	MISSENSE	272	272	0			nsp2	produced by both pp1a and pp1ab		266	T=6	6	T	C	monoclonal antibody serial passage escape	Greaney et al. (2020)	https://doi.org/10.1016/j.chom.2020.11.007		Ranked effective escape variant in the RBD for highly neutralizing COV2-2499 monoclonal antibody	False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
S4507S	g.A13521G	p.S4507S			13785	ORF1ab	ORF1b	SILENT	272	272	0			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		141	G=131	131	G	A						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
S477N	g.G1430A	p.S477N			22992	S	S	MISSENSE	272	272	0						255	A=17	17	A	G	ACE2 host variant dependency	Barton et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1		This mutation's measured interaction affinity with ACE2:p.S19P (0.03% minor allele frequency,  found almost exclusively in African/African-Americans in the GnomAD database) was significantly lower than the predicted value,  indicating that these mutations were not independent. This is consistent with the fact that the ACE2 residue S19  is adjacent to RBD residue S477 in the contact interface. 	False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
S477N	g.G1430A	p.S477N			22992	S	S	MISSENSE	272	272	0						255	A=17	17	A	G	ACE2 receptor binding affinity		https://doi.org/10.1016/j.cell.2020.08.012		Increased affinity for ACE2: clade in Australia 2020-05-27 onward, clade in Europe 2020-08-08 onward Modelling shows flexible region in Spike RBD with residue S477 having the greatest rotational flexibility.	False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
S477N	g.G1430A	p.S477N			22992	S	S	MISSENSE	272	272	0						255	A=17	17	A	G	ACE2 receptor binding affinity	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, ACE2 binding affinity increased 0.06 fold	False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
S477N	g.G1430A	p.S477N			22992	S	S	MISSENSE	272	272	0						255	A=17	17	A	G	ACE2 receptor binding affinity	Zahradnik et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.06.425392		Among the first selected minor variants in an in vitro evolution experiment for ACE2 binding, with increasing proportion in subsequent rounds.	False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
S477N	g.G1430A	p.S477N			22992	S	S	MISSENSE	272	272	0						255	A=17	17	A	G	antibody epitope effects	Gaebler et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2		Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant. 	False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
S477N	g.G1430A	p.S477N			22992	S	S	MISSENSE	272	272	0						255	A=17	17	A	G	antibody epitope effects	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2		Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows some resistence across all antibodies tested.	False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
S477N	g.G1430A	p.S477N			22992	S	S	MISSENSE	272	272	0						255	A=17	17	A	G	convalescent plasma escape	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2		Mixed bag of mild positive and negative changes in neutralization capability of all 4 convalescent sera tested. Against a wider panel of 16 convalescent plasma (no replicates), 10 show low neutralization.	False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
S477N	g.G1430A	p.S477N			22992	S	S	MISSENSE	272	272	0						255	A=17	17	A	G	convalescent plasma escape	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2		Strong reduction in neutralization capability of all 4 convalescent sera tested (2 ablations).	False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
S477N	g.G1430A	p.S477N			22992	S	S	MISSENSE	272	272	0						255	A=17	17	A	G	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'D614G'	Lentiviral pseudotyped with the key mutations from 20A.EU2 lineage was neutralized slightly less than D614G in 10 convalescent sera from April 2020 infectees.	False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
S477N	g.G1430A	p.S477N			22992	S	S	MISSENSE	272	272	0						255	A=17	17	A	G	convalescent plasma escape	Zhou et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1	'L5F', 'T95I', 'D253G', 'D614G', 'A701V'	"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed no significant  change in IC50 serum dilution concentration for 6 convalescent sera."	False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
S477N	g.G1430A	p.S477N			22992	S	S	MISSENSE	272	272	0						255	A=17	17	A	G	gene expression increase	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, Spike gene expression increased 0.06 fold	False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
S477N	g.G1430A	p.S477N			22992	S	S	MISSENSE	272	272	0						255	A=17	17	A	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	'E484K'	Bamlanivimab (LY-CoV555) lost ~10x binding against this double mutation. Tixagevimab lost ~16x binding against this double mutation.	False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
S477N	g.G1430A	p.S477N			22992	S	S	MISSENSE	272	272	0						255	A=17	17	A	G	reinfection	Fournier et al. (2021)	https://doi.org/10.1016/j.ijid.2021.03.068	'D614G'	"11 cases of re-infection with the ""Marseille-4"" variant found within 1028 positive tests, where all of the earlier infections were from different strains. This lineage is also characterized by N:p.M234I:A376T"	False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
S477N	g.G1430A	p.S477N			22992	S	S	MISSENSE	272	272	0						255	A=17	17	A	G	symptom prevalence	Fournier et al. (2021)	https://doi.org/10.1016/j.ijid.2021.03.068	'D614G'	Compared to the clade 20A strains that predominated during phase 1 between March and May 2020, the Marseille-4 variant (characterized  by this mutation plus N:p.M234I:A376T) was associated with a lower frequency of cough, rhinitis, and olfactory and gustatory disorders.  By contrast, hypoxemia was more frequent in patients infected with the Marseille-4 variant.	False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
S477N	g.G1430A	p.S477N			22992	S	S	MISSENSE	272	272	0						255	A=17	17	A	G	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'D614G'	Lentiviral pseudotyped with the key mutations from 20A.EU2 lineage was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no significant change in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.	False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
S477N	g.G1430A	p.S477N			22992	S	S	MISSENSE	272	272	0						255	A=17	17	A	G	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'L5F', 'T95I', 'D253G', 'D614G', 'A701V'	Neutralization efficiency (ID50) against B.1.526 reduced 2.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
S477N	g.G1430A	p.S477N			22992	S	S	MISSENSE	272	272	0						255	A=17	17	A	G	vaccine neutralization efficacy	Zhou et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1	'L5F', 'T95I', 'D253G', 'D614G', 'A701V'	"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed no significant change in IC50 serum dilution concentration for sera from BNT162b2 (Pzifer) or mRNA1273 (Moderna) vacinees collected 28 days following booster dose."	False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
S477N	g.G1430A	p.S477N			22992	S	S	MISSENSE	272	272	0						255	A=17	17	A	G	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is 0.22 kcal/mol (i.e. stabilizing relative to wild type) 	False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
S6725G	g.A20173G	p.S6725G			20437	ORF1ab	ORF1b	MISSENSE	268	272	0			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only		237	G=31	31	G	A						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
S994R	g.T2982G	p.S994R			3247	ORF1ab	ORF1a	MISSENSE	271	272	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		260	G=11	11	G	T						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
SL31X	g.CAC92_94GAT	p.SL31X			27847	ORF7b	ORF7b		272	272	0						141	GAT=3	3	GAT	CAC						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
T11I	g.C32T	p.T11I			27925	ORF8	ORF8	MISSENSE	272	272	0						0	T=272	272	T	C						False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
T1820I	g.C5459T	p.T1820I			5724	ORF1ab	ORF1a	MISSENSE	272	272	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		267	T=5	5	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
T1876A	g.A5626G	p.T1876A			5891	ORF1ab	ORF1a	MISSENSE	271	272	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		266	G=5	5	G	A						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
T265I	g.C794T	p.T265I			1059	ORF1ab	ORF1a	MISSENSE	272	272	0			nsp2	produced by both pp1a and pp1ab		0	T=272	272	T	C						False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
T366I	g.C1097T	p.T366I			29370	N	N	MISSENSE	272	272	0						265	T=7	7	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
T4304I	g.C12911T	p.T4304I			13176	ORF1ab	ORF1a	MISSENSE	272	272	0			nsp10	nsp10_CysHis, formerly known as growth-factor-like protein (GFL), produced by both pp1a and pp1ab		261	T=11	11	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
T4640T	g.C13920T	p.T4640T			14184	ORF1ab	ORF1b	SILENT	272	272	0			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		270	T=2	2	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
T6938I	g.C20813T	p.T6938I			21077	ORF1ab	ORF1b	MISSENSE	271	272	0			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only		269	T=2	2	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
T723T	g.C2169T	p.T723T			23731	S	S	SILENT	271	272	0						268	T=3	3	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
T95I	g.C284T	p.T95I			21846	S	S	MISSENSE	272	272	0						0	T=272	272	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x decrease in binding (KD) relative to D614G.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
T95I	g.C284T	p.T95I			21846	S	S	MISSENSE	272	272	0						0	T=272	272	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L5F', 'D253G', 'E484K', 'A701V'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.526) showed a 1.78x increase  in binding (KD) relative to D614G, even though each variant independently decreases binding.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
T95I	g.C284T	p.T95I			21846	S	S	MISSENSE	272	272	0						0	T=272	272	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
T95I	g.C284T	p.T95I			21846	S	S	MISSENSE	272	272	0						0	T=272	272	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L5F', 'D253G', 'E484K', 'A701V'	This variant combination (representing lineage B.1.526) showed a 1.02x increase in Spike binding (relative  to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
T95I	g.C284T	p.T95I			21846	S	S	MISSENSE	272	272	0						0	T=272	272	T	C	convalescent plasma escape	Zhou et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1	'L5F', 'D253G', 'E484K', 'D614G', 'A701V'	"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.8x reduction in  IC50 serum dilution concentration for 6 convalescent sera."	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
T95I	g.C284T	p.T95I			21846	S	S	MISSENSE	272	272	0						0	T=272	272	T	C	convalescent plasma escape	Zhou et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1	'L5F', 'D253G', 'S477N', 'D614G', 'A701V'	"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed no significant  change in IC50 serum dilution concentration for 6 convalescent sera."	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
T95I	g.C284T	p.T95I			21846	S	S	MISSENSE	272	272	0						0	T=272	272	T	C	outcome hazard ratio	Yang et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.08.04.21261596v1	'D253G', 'D614G'	B.1.526 (Iota) substantially increased IFR in older adults: by 46% (95% CI: 7.4 – 84%) among 45-64 year-olds,  82% (95% CI: 20 – 140%) among 65-74 year-olds, and 62% (95% CI: 45 – 80%) among 75+ during Nov 2020 – Apr 2021,  compared to baseline IFR estimated for preexisting variants. [minimum clade defining mutations listed]	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
T95I	g.C284T	p.T95I			21846	S	S	MISSENSE	272	272	0						0	T=272	272	T	C	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'L5F', 'D253G', 'S477N', 'D614G', 'A701V'	Neutralization efficiency (ID50) against B.1.526 reduced 2.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
T95I	g.C284T	p.T95I			21846	S	S	MISSENSE	272	272	0						0	T=272	272	T	C	vaccine neutralization efficacy	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L5F', 'D253G', 'E484K', 'D614G', 'A701V'	2.3x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
T95I	g.C284T	p.T95I			21846	S	S	MISSENSE	272	272	0						0	T=272	272	T	C	vaccine neutralization efficacy	Pegu et al (2021)	https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1	'L5F', 'D253G', 'E484K', 'D614G', 'A701V'	Detectable antibodies against B.1.526+E484K at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 43 100%, Day 209 88%.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
T95I	g.C284T	p.T95I			21846	S	S	MISSENSE	272	272	0						0	T=272	272	T	C	vaccine neutralization efficacy	Zhou et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1	'L5F', 'D253G', 'E484K', 'D614G', 'A701V'	"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.6x reduction in both IC50 serum dilution concentration for sera from 5 BNT162b2 (Pzifer) or 3 mRNA1273 (Moderna) vacinees collected 28 days following booster dose."	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
T95I	g.C284T	p.T95I			21846	S	S	MISSENSE	272	272	0						0	T=272	272	T	C	vaccine neutralization efficacy	Zhou et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1	'L5F', 'D253G', 'S477N', 'D614G', 'A701V'	"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed no significant change in IC50 serum dilution concentration for sera from BNT162b2 (Pzifer) or mRNA1273 (Moderna) vacinees collected 28 days following booster dose."	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
T95I	g.C284T	p.T95I			21846	S	S	MISSENSE	272	272	0						0	T=272	272	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
T95I	g.C284T	p.T95I			21846	S	S	MISSENSE	272	272	0						0	T=272	272	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L5F', 'D253G', 'E484K', 'A701V'	This variant combination (representing lineage B.1.526) showed a 1.34x increase in Spike binding (relative  to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
V11V	g.C33T	p.V11V			21595	S	S	SILENT	272	272	0						263	T=9	9	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
V127F	g.G379T	p.V127F			21941	S	S	MISSENSE	272	272	0						258	T=14	14	T	G						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
V392V	g.G1176T	p.V392V			29449	N	N	SILENT	272	272	0						270	T=2	2	T	G						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
V4649A	g.T13946C	p.V4649A			14210	ORF1ab	ORF1b	MISSENSE	272	272	0			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		270	C=2	2	C	T						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
V5545G	g.T16634G	p.V5545G			16898	ORF1ab	ORF1b	MISSENSE	272	272	0			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		238	G=34	34	G	T						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
V868L	g.G2602T	p.V868L			2867	ORF1ab	ORF1a	MISSENSE	271	272	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		264	T=7	7	T	G						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
Y1337Y	g.C4011T	p.Y1337Y			4276	ORF1ab	ORF1a	SILENT	272	272	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		267	T=5	5	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
Y189C	g.A566G	p.Y189C			25958	ORF3a	ORF3a	MISSENSE	272	272	0						270	G=2	2	G	A						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
Y4172Y	g.C12516T	p.Y4172Y			12781	ORF1ab	ORF1a	SILENT	272	272	0			nsp9	ssRNA-binding protein, produced by both pp1a and pp1ab		268	T=4	4	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
Y5867Y	g.T17601C	p.Y5867Y			17865	ORF1ab	ORF1b	SILENT	270	272	0			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		266	C=4	4	C	T						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
Y6776Y	g.T20328C	p.Y6776Y			20592	ORF1ab	ORF1b	SILENT	266	272	0			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only		263	C=3	3	C	T						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
Y6813Y	g.C20439T	p.Y6813Y			20703	ORF1ab	ORF1b	SILENT	271	272	0			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only		261	T=10	10	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
Y837Y	g.T2511C	p.Y837Y			24073	S	S	SILENT	271	272	0						226	C=45	45	C	T						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
Y86Y	g.C258T	p.Y86Y			28531	N	N	SILENT	272	272	0						137	T=135	135	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
g.A29815G	g.A29815G				29815	intergenic	intergenic		95	272	0	mask	seq_end				94	G=1	1	G	A						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
g.C-126T	g.C-126T				140	ORF1ab	intergenic		272	272	0						269	T=3	3	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
g.C-156T	g.C-156T				110	ORF1ab	intergenic		272	272	0						141	T=131	131	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
g.C-25T	g.C-25T				241	ORF1ab	intergenic		271	272	0						0	T=271	271	T	C						False	B.1.526	B.1.526=True	de_escalated	24-Mar-2021		
g.C29732T	g.C29732T				29732	intergenic	intergenic		272	272	0						246	T=26	26	T	C						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
g.G-15T	g.G-15T				29543	ORF10	intergenic		272	272	0						141	T=131	131	T	G						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
g.G29715A	g.G29715A				29715	intergenic	intergenic		272	272	0						141	A=131	131	A	G						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
g.G29764T	g.G29764T				29764	intergenic	intergenic		134	272	0						133	T=1	1	T	G						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
g.G29781A	g.G29781A				29781	intergenic	intergenic		95	272	0						94	A=1	1	A	G						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
g.GCCACGCGGAGTACGATCGAGTGTA29737GA	g.GCCACGCGGAGTACGATCGAGTGTA29737GA				29737	intergenic	intergenic		255	272	0						127	GA=9	9	GA	GCCACGCGGAGTACGATCGAGTGTA						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
g.GCCACGCGGAGTACGATCGAGTGTA29737TCCACGCGGAGTACGATCGAGTGTA	g.GCCACGCGGAGTACGATCGAGTGTA29737TCCACGCGGAGTACGATCGAGTGTA				29737	intergenic	intergenic		255	272	0						127	TCCACGCGGAGTACGATCGAGTGTA=119	119	TCCACGCGGAGTACGATCGAGTGTA	GCCACGCGGAGTACGATCGAGTGTA						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
g.T-61C	g.T-61C				205	ORF1ab	intergenic		272	272	0						262	C=10	10	C	T						False	B.1.526	B.1.526=False	de_escalated	24-Mar-2021		
